Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00067860 · ClinicalTrials.gov registry record · Phase 2

Diet/Growth Factor Mechanisms of Gut Adaptation

A Phase 2 study, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
27
Enrollment target

NCT00067860 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00067860, a Phase 2 study, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
27 participants
Enrollment target

Study Summary

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.

Interventions

  • DRUG recombinant human growth hormone
  • BEHAVIORAL diet modification

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 1996-10
Est. Completion 2006-12
Phase Phase 2

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT00067860

The ClinicalTrials.gov registry entry for NCT00067860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which recombinant human growth hormone is the first listed.

NCT00067860 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00067860 about?

NCT00067860 is a clinical study titled "Diet/Growth Factor Mechanisms of Gut Adaptation". This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints includ...

What is the current status of trial NCT00067860?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 1996-10. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00067860?

The interventions under investigation include: recombinant human growth hormone (DRUG), diet modification (BEHAVIORAL).

Who is sponsoring clinical trial NCT00067860?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.